|
Dec 13
|
SNY's Tolebrutinib Gets FDA Breakthrough Therapy Tag for nrSPMS
|
|
Dec 13
|
Novavax Cut Its Outlook Despite Beating Third-Quarter Forecasts. Is It A Sell In December 2024?
|
|
Dec 13
|
Press Release: Tolebrutinib designated Breakthrough Therapy by the FDA for non-relapsing secondary progressive multiple sclerosis
|
|
Dec 12
|
Gilead appoints Sanofi official Dietmar Berger as next chief medical officer
|
|
Dec 12
|
Sanofi’s combo vaccines gain FDA fast track designation
|
|
Dec 11
|
FDA Grants Fast Track Tag to SNY's Two COVID & Flu Vaccine Candidates
|
|
Dec 11
|
NVAX Starts Late-Stage Study on COVID-19-Flu Combo & Flu Vaccines
|
|
Dec 11
|
Press Release: Two combination vaccine candidates for prevention of influenza and COVID-19 granted Fast Track designation in the US
|
|
Dec 10
|
RSV prophylactic market to reach $6.2bn in 8MM by 2030
|
|
Dec 9
|
Press Release: ASH: Sarclisa combinations demonstrated significant benefits in newly diagnosed multiple myeloma patients
|
|
Dec 9
|
Sanofi’s Phase III trial of rilzabrutinib for thrombocytopenia meets endpoint
|
|
Dec 7
|
Press Release: ASH: rilzabrutinib demonstrated significant patient benefit in the first positive phase 3 study of a BTK inhibitor in ITP
|
|
Dec 6
|
Why Is Denali Therapeutics (DNLI) Down 21.2% Since Last Earnings Report?
|
|
Dec 6
|
Denali Starts Dosing in Phase II Parkinson's Disease Study
|
|
Dec 6
|
Press Release: Availability of the revised financial statements for Sanofi excluding Opella
|